Eli Lilly's Growth Rate Is Fantastic, but This Number Is Even Better
Eli Lilly (NYSE: LLY) is a growth machine, with its business taking off due to its wildly successful diabetes drug Mounjaro, which recently was approved for weight-loss treatment under the name Zepbound. It could end up being the company's top seller in the near future. There is no shortage of reasons to be bullish on the company.
Its sales have been rising at a rapid rate. But as impressive as its growth has been, there's another number that looks even better -- one that investors should pay attention to, and which could ensure its valuation continues to rise significantly.
For the three-month period ended June 30, Lilly's revenue increased by 36% year over year to $11.3 billion, thanks in large part to the growth in Mounjaro and Zepbound. But what was particularly impressive was that the company's operating income increased even faster: 75%, rising to $3.7 billion.
Source Fool.com
